Other

Bavarian Nordic A/s

Gsf-forschungszentrum Fur Umwelt Und Gesundheit, Gmbh

Gsf-forschungszentrum Fuer Umwelt Und Gesundheit Gmbh

Bavarian Nordic Research Institute Gmbh

Institut Fur Virologie

Gsf-gessellschaft Fur Umwelt Und Gesundheit Gmbh

Bavarian Nordic Research Inst. A/s

Gsf-forschungszentrum Fuer Umwelt Und Gesendheit Gmbh

Brian Salmons

Robert Saller

Walter H G&uuml;nzburg

Dieter Klein

Peter Karle

Walter Henry Günzburg

Matthias Löhr

Jorg G Baumann

Walter H Gunzburg

Walter Tabotta

Sabine Goller

Peter M&uuml;ller

Marc Piechaczyk

Peter Müller

Matthias L&ouml;hr

Mariana Marin

Walter Gunzburg

Mireia Pelegrin

The present invention relates to retroviral vectors carrying DNA sequences encoding SDI-1, function analogues of SDI-1, or fragments thereof, or antisense SDI-1 DNA sequences, and especially retroviral vectors carrying the SDI-1 or antisense SDI-1 sequences under the transcriptional control of target cell specific regulatory elements or promoters or X-ray inducible promoters. Further, the invention relates to the use of such retroviral vectors for the production of recombinant retroviral particles useful for the treatment of disorders or diseases responsive to the anti-proliferative activity of SDI-1, or the proliferative activity of antisense SDI-1 sequences.

Retroviral vectors carrying senescent cell derived inhibitors 1 (SDI-1)or antisense SDI-1 nucleotide sequences

The present invention relates to capsules encapsulating cytochrome P450 producing cells and cytochrome P450 producing retroviral packaging cells. Furthermore, the present invention relates to the treatment of cancer or any other relevant disease with said capsules and to the use of said capsules for the preparation of a pharmaceutical composition for said treatment.

Encapsulated cells producing cytochrome P450

The present invention relates to a retroviral vector which is especially applicable as a safe gene transfer vehicle for targeted gene therapy. Said retroviral vector comprises one or more promoters inserted in antisense orientation within the 5&prime; LTR region and one or more coding sequences inserted in antisense orientation within the 3&prime; LTR region. Both, the promoter as well as the coding sequence, are additionally inserted in such a way as to ensure that the promoter and the coding sequence become duplicated during the process of reverse transcription in a target cell and thus appear in the 3&prime; as well as in the 5&prime; LTR region of the resulting provirus in a fashion where the promoter is located upstream of the coding sequence allowing it to drive gene expression. This system avoids any leakiness of gene expression in the packaging cells, and allows expression of transferred genes in the target cell without the necessity for external stimuli.

Reconstituting retroviral vector (recon vector) for targeted gene expression

The present invention relates to encapsulated cells producing viral particles, especially retroviral particles containing the genome of a retroviral vector carrying therapeutic genes, to methods for the preparation of such encapsulated cells, as well as to the use of such encapsulated cells for the delivery of genes, especially therapeutic genes, to target organs/cells.

Encapsulated cells producing viral particles

The invention refers to a novel recombinant vectors useful for gene therapy of viral infections and of diseases associated with B and T cells. The present invention relates, furthermore, to novel usages of the two products of the open reading frame of mouse mammary tumour virus.

Vectors that repress heterologous promoter activity

The present invention relates to a retroviral vector encoding heterologous genes particularly for gene therapy of genetic defects or viral infections.

Targeted integration into chromosomes using retroviral vectors

The present invention relates to capsules encapsulating antibody-producing cells, and to use of such capsules and encapsulated cells, respectively, for implantation in vivo for long term delivery or sustained delivery of antibodies of therapeutic interest.

Encapsulated cells producing antibodies

The present invention relates to a retroviral vector system comprising a packaging cell line that synthesize the core and enzymatic proteins of MLV virus from one or more gag and pol containing constructs and the envelope of MMTV virus from the same or an independent env containing construct, and to pseudotyped retroviral particles produced by culturing said retroviral vector system transfected with a MLV based retroviral vector, and isolation of said pseudotyped retroviral particles.

Pseudotyped retroviral particles

Growing community of inventors

Ainhofen, Germany

Brian Salmons